FIRST ACCEPTED ABSTRACTS

FIRST ACCEPTED ABSTRACTS

See the first research works accepted for presentation at ICLE 2018 and their allocation per categories. 

Do not miss the chance to be among them and submit your abstract now! 



ICLE8-0005
Genome editing for allogeneic ACT

THE LANGUAGE OF LYMPHOCYTE ENGINEERING
P. Mugüerza1
1Freelance, Freelance, Valladolid, Spain
 _______________________________________________________

ICLE8-0008
Other

COMPREHENSIVE ANALYSIS OF STARTING MATERIALS FOR GENE-MODIFIED CELL-BASED IMMUNOTHERAPIES
A. Luostarinen1, S. Ylä-Herttuala2, J. Nystedt1, T. Kaartinen1
1Finnish Red Cross Blood Service, Advanced Cell Therapy Centre, Helsinki, Finland
2A.I. Virtanen Institute for Molecular Sciences- University of Eastern Finland, Department of Biotechnology and Molecular Medicine, Kuopio, Finland
_______________________________________________________

ICLE8-0009
Solid tumours

A CAR-T CELL THERAPY TARGETING GLYPICAN-3 POSITIVE HEPATOCELLULAR CARCINOMA
B. Wang1, E. Ngoh1, M.K. Soh1, Y. Yeap1, H. Huang1, H.C. Tan1, Y. Hu1, C.I. Wang1
1Singapore Immunology Network- Agency for Science- Technology and Research ASTAR, Human Monoclonal Antibodies Platform, Singapore, Singapore
_______________________________________________________

ICLE8-0011
Other

Clinical-grade Aspergillus-specific T cells: Switch from magnetic selection with lysate to short term expansion procedure with peptide pools
C. Hoffmann-Freimüller1, R. Geyeregger1, S. Tischer2,3, N. Frank1, J. Stemberger1, B. Maecker-Kolhoff3,4, R. Blasczyk2,3, G. Fritsch1, B. Eiz-Vesper2,3
1St. Anna Kinderkrebsforschung e.V.- Children´s Cancer Research Institute, Medical University, Vienna, Austria
2Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany
3Integrated Research and Treatment Center IFB-Tx, Hannover Medical School, Hannover, Germany
4Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

 _______________________________________________________

ICLE8-0012
Target and receptor discovery

OPTIMISING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR HAEMATOLOGICAL MALIGNANCIES
A. Bahashwan1, M. Kalaitsidou1, A. Schutt1, D. Gilham1, R. Hawkins1
1The University of Manchester, Division of Cancer Sciences- Faculty of Biology- Medicine and Health, Manchester, United Kingdom

_______________________________________________________

ICLE8-0014
Genome editing for allogeneic ACT

TIM-3 TARGETING CAR-T CELLS, AS A POTENTIAL IMMUNOTHERAPY FOR AML.
S. Lee1, Z.Y. Ye1, H. Huang1, M.K. Soh1, Cheng-I WANG1

1ASTAR, Singapore Immunology Network SIgN, Singapore, Singapore
_______________________________________________________

ICLE8-0018
Other

CUMULATIVE CHEMOTHERAPY DEPLETES NAÏVE T CELLS : IMPLICATIONS FOR CELLULAR THERAPY
D. Barrett1, R. Das1, J. Storm1
1Children's Hospital of Philadelphia, Oncology, Philadelphia, USA
_______________________________________________________

ICLE8-0019
Solid tumours

GENETIC ENGINEERING OF TUMOUR INFILTRATING LYMPHOCYTES (TIL) WITH A NOVEL GROWTH FACTOR RECEPTOR FOR TREATMENT OF SOLID TUMOURS
M. Le Brocq1, G. Owens2, J. McCaffrey1, A. Patel1, R.D. Guest1, R.E. Hawkins1,2, J.S. Bridgeman1
1Immetacyte, Research & Development, Manchester, United Kingdom
2University of Manchester, Division of Cancer Sciences, Manchester, United Kingdom

_______________________________________________________

ICLE8-0020
Other

Optimisation of Cytokine-dependent Expansion for TCR-Transduced Autologous T-cells
R. Petrovic1, D. Biziato1, A. Toufexi1, J. Kerby1
1Catapult Cell & Gene Therapy, Process Development, London, United Kingdom

_______________________________________________________

ICLE8-0022
Hematological malignancies

DETECTION NPM1 MUTATION AND CLINICAL CHARACTERS IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THE MONGOLIA
S. Oyunbileg1,2, B. Davaabayar2, N. Oyunderlger1, B. Sevjidmaa2
1Center of hematology and bone marrow transplantation, The First central hospital og Mongolia, ulaanbaatar, Mongolia
2Physiology, Mongolian National Unniversity of Medical Science, ulaanbaatar, Mongolia
_______________________________________________________

ICLE8-0033
Other

Impact of the signal strength and temperature during T lymphocytes activation and proliferation - study on companion dog model
I. Szopa1, J. Bujak1, A. Łabędź1, K. Majchrzak1
1Warsaw University of Life Sciences- Faculty of Veterinary Medicine, Department of Physiological Sciences, Warsaw, Poland
_______________________________________________________

ICLE8-0034
Hematological malignancies

DETECTION FLT3/ITD MUTATION AND CLINICAL CHARACTERS IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THE MONGOLIA
S. Oyunbileg1, B. Davaabayar2, B. Khishigjargal1, N. Oyundelger1, B. Sevjidmaa2
1Center of hematology and bone marrow transplantation, The First central hospital og Mongolia, ulaanbaatar, Mongolia
2Physiology, Mongolian National Unniversity of Medical Science, ulaanbaatar, Mongolia

 _______________________________________________________

ICLE8-0036
Other

EXPRESSION AND FUNCTIONAL DYNAMICS OF TRPV1 ION CHANNEL IN THE CANINE PBMC
J. Bujak1, P. Bednarczyk2, D. Kosmala1, I. Szopa1, K. Majchrzak1
1Warsaw University of Life Sciences, Department of Physiological Sciences, Warsaw, Poland
2Warsaw University of Life Sciences, Department of Biophysics, Warsaw, Poland

ICLE8-0007
Hematological malignancies

SUPER-RESOLUTION MYCRSOCOPY DSTORM REVEALS CD19DIM EXPRESSION ON A SUBSET OF MYELOMA CELLS THAT CAN BE TARGETED WITH CD19-CAR T cells
T. Nerreter1, L. Sebastian2, S. Doose2, S. Danhof1, H. Einsele1, M. Sauer2, M. Hudecek1
1University Hospital of Wuerzburg, Medicine II, Wuerzburg, Germany
2Julius-Maximilians-University Wuerzburg, Department of Biotechnology and Biophysics, Wuerzburg, Germany

_______________________________________________________

ICLE8-0010
Solid tumours

ACTIVE MODULATION OF THE TUMOR MICROENVIRONMENT BY ENGINEERED T CELLS
E. Ceccarello1, T. Tabaglio1, D.W.K. Boon2, W.K.L. Teo1, D.Z.M. Tan1, J.J.Y. Aw1, S.S.F. Koh3, A. Pavesi1, E. Guccione1, A. Bertoletti4
1Agency for Science- Technology and Research, Institute of Molecular and Cell Biology, Singapore, Singapore
2Agency for Science- Technology and Research, Institute of High Performance Computing, Singapore, Singapore
3Lion TCR Pte LTD, Lion TCR Pte LTD, Singapore, Singapore
4Duke-Nus Medical School, Emerging Infectious Disease, Singapore, Singapore

_______________________________________________________

ICLE8-0013
Solid tumours

ADOPTIVE T-CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
L. Rousso Noori1
1The George S. Wise Faculty of Life Sciences- Tel Aviv University, Department of Biochemistry and Molecular Biology, Tel Aviv, Israel

_______________________________________________________

ICLE8-0017
Target and receptor discovery

SURFACE MOBILITY AND CLUSTER FORMATION OF VARIOUS MELANOMA ASSOCIATED ANTIGENS MODULATES CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELL ACTIVATION
A. Szoor1, A. Holzinger2, A. Pham1, H. Abken2, G. Vereb1
1University of Debrecen, Department of Biophysics and Cell Biology, Debrecen, Hungary
2University of Cologne Center for Molecular Medicine, Department I. of Internal  Medicine, Cologne, Germany 

_______________________________________________________

ICLE8-0026
Hematological malignancies

LYMPHOCYTE-SPECIFIC DELIVERY OF PROTEIN THERAPEUTICS BY GENETICALLY ENGINEERED EXOSOMES
D. Levy1, M. Do1, B. Lu1
1Santa Clara University, Department of Bioengineering, Santa Clara, USA

_______________________________________________________

ICLE8-0027
Hematological malignancies

Post-transplant Immunotherapy with WT1-specific CTLs for High-risk Acute Myelogenous Leukemia: A Prospective Clinical Phase I/II trial
H.J. Kim1, H.J. Sohn2, J.A. Hong2, H.J. Lee2, D.H. Sohn3, C.A. Shin3, S.J. Hyun3, C.H. Hong3, H. Choi3, A.R. Shin3, H.I. Cho2, W.S. Min1, T.G. Kim3
1College of Medicine- The Catholic University of Korea, Leukemia Research Institute- Seoul St. Mary's Hospital, Seoul, Republic of Korea
2College of Medicine- The Catholic University of Korea, Catholic Hematopoietic Stem Cell Bank, Seoul, Republic of Korea
3College of Medicine- The Catholic University of Korea, Microbiology and Immunology, Seoul, Republic of Korea
_______________________________________________________


ICLE8-0029
Non-viral vectors and transposons

Generation of Wilms' Tumor 1 TCR-redirected CD4 and gamma-delta T cells by RNA electroporation and co-transfer of CD8 mRNA
D. Campillo1, G. Roex1, H.H. Van Acker1, Z.N. Berneman1,2,3, E. Lion1,2, V.F.I. Van Tendeloo1
1University of Antwerp, Vaccine and Infectious Disease Institute, Antwerp, Belgium
2Antwerp University Hospital, Center for Cell Therapy and Regenerative Medicine, Edegem, Belgium
3Antwerp University Hospital, Division of Hematology, Edegem, Belgium
_______________________________________________________


ICLE8-0032
Solid tumours

Fine-tuning of CD28 signaling motifs increases anti-tumor activity and persistence of Chimeric Antigen Receptor-modified T cells
S. Guedan1,2, A. Posey2, A. Wing2, V. Casado-Medrano3, C. Shaw2, R.M. Young2, C.H. June2
1IDIBAPS, Oncology and Hematology, Barcelona, Spain
2University of Pennsylvania, Center for Cellular Immunotherapies, Philadelphia, USA
3University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, USA
_______________________________________________________

ICLE8-0035
Solid tumours

IMPROVING CEA-TARGETED CAR-T CELL THERAPY FOR SOLID TUMOURS
W. Zheng1, G. Kueberuwa1, E. Cheadle1, A. Armstrong2, R.E. Hawkins1
1University of Manchester, Department Cancer Sciences, Manchester, United Kingdom
2The Christie NHS Foundation Trust, Department of Medical Oncology, Manchester, United Kingdom

_______________________________________________________

ICLE8-0037
Safety switches and controlled expression

ELIMINATION OF CAR-ENGINEERED LYMPHOCYTES BY AUTOLOGOUS ANTI-CAR T CELLS
S. Koristka1, P. Ziller-Walter2, A. Feldmann1, C. Arndt1, A. Kegler1, S. Albert2, G. Ehninger3,4, M. Bornhäuser3,4, M. Bachmann1,2,4
1Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
2UniversityCancerCenter UCC `Carl Gustav Carus' Technische Universität Dresden, Tumor Immunology, Dresden, Germany
3University Hospital `Carl Gustav Carus' Technische Universität Dresden, Medical Clinic and Policlinic I, Dresden, Germany
4German Cancer Research Center DKFZ and German Cancer Consortium DKTK, partner site Dresden, Heidelberg, Germany
_______________________________________________________

ICLE8-0042
Solid tumours

CAR-T cell immunotherapy in solid tumors: Colorectal Cancer
E. Ponterio1, C. Valvo1, M. Cappellari2, L. Pasquini2, A. Boe2, P. Romania2, E. Petrucci2, C. Amoreo3, M.R. Sciuto2, R. Dattilo4, E. Pilozzi5, L. Ricci-Vitiani2, M. Biffoni2, R. De Maria1, T.L. Haas1
1Catholic University of the Sacred Heart, Institute of General Pathology, Rome, Italy
2Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, Rome, Italy
3"Regina Elena" National Cancer Institute, Department of Pathology, Rome, Italy
4"Regina Elena" National Cancer Institute, Unit of Tumor Immunology and Immunotherapy, Rome, Italy
5Sapienza University, Department of Experimental Medicine, Rome, Italy
_______________________________________________________

ICLE8-0043
Hematological malignancies

Engineering CD38low Natural Killer cells to transiently express CD16 (F158V) m-RNA enhances the cytotoxic potential of Daratumumab against Multiple Myeloma with minimal NK cell fratricide
S. Sarkar1, S. Chauhan1, A. Natoni1, J. Daly1, R. Henderson1, M. O'Dwyer1
1National University of Ireland- Galway, Apoptosis Research Centre, Galway, Ireland
_______________________________________________________

ICLE8-0044
Safety switches and controlled expression

Development and characterization of novel anti-GD2 target modules for retargeting of Universal CAR T cells toward GD2 expressing tumors
N. Mitwasi1, A. Feldmann1, R. Bergmann1, N. Berndt1, C. Rössig2, M. Bachmann1,3,4,5
1Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
2Münster University Hospital UKM, Department of Pediatric Hematology and Oncology, Münster, Germany
3University Cancer Center UCC 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany
4German Cancer Research Center DKFZ, n, Heidelberg, Germany
5German Cancer Consortium DKTK, partner site Dresden, Dresden, Germany
_______________________________________________________


ICLE8-0046
Solid tumours

Targeting Multiple Tumors and Viral Infected Cells Using T-Cells Engineered to Express a NCR-Based Chimeric Antigen Receptor
V. Eisenberg1, S. Hoogi1, S. Mayer1, K. Shamalov1, T. Barliya1, A. Pogrador2, C.J. Cohen1
1Bar Ilan University, The Mina & Everard Goodman Faculty of Life Sciences, Ramat Gan, Israel
2Ben-Gurion University of Negev, Faculty of Health Sciences, Beer Sheva, Israel
 


ICLE8-0015
Non-viral vectors and transposons

Vapor nanobubble photoporation as a new, safe and efficient technique for the delivery of small interfering RNA to cytotoxic T cells
J. Van Hoeck1, L. Wayteck1, R. Xiong1, K. Braeckmans1, S.C. De Smedt1, K. Raemdonck1
1Ghent University, Faculty of Pharmaceutical Sciences, Ghent, Belgium

_______________________________________________________

ICLE8-0016
Target and receptor discovery

HARNESSING CD8 CO-RECEPTOR FUNCTION FOR IMMUNOTHERAPY WITH LOW-AVIDITY TCR TRANSGENIC T CELLS
G. Bajwa1, E. Hoyer1, D. Brenner1, M. Martinez-Paniagua2, N. Nouraee1, F. Sadeghi2, I. Gruber3, M. Hebeisen3, N. Rufer3, M.F. Wu4, W. Tao4, N. Varadarajan2, M. Brenner1, C. Arber3
1Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, USA
2University of Houston, Department of Chemical and Biomolecular Engineering, Houston, USA
3Ludwig Institute for Cancer Research Lausanne- Lausanne University Hospital and University of Lausanne, Department of oncology UNIL CHUV, Lausanne, Switzerland
4Baylor College of Medicine, Department of Biostatistics, Houston, USA

_______________________________________________________

ICLE8-0021
Solid tumours

CHIMERIC ANTIGEN RECEPTORS WITH A MYD88 AND CD40 ENDODOMAIN ENDOW T CELLS WITH SUPERIOR ANTITUMOR ACTIVITY
B. Prinzing1, G. Krenciute1, S. Gottschalk1
1St. Jude Children's Research Hospital, Bone Marrow Transplantation & Cellular Therapy, Memphis, USA

_______________________________________________________

ICLE8-0023
Non-viral vectors and transposons

CRISPR/Cas9 unites with Sleeping Beauty to generate CAR T cells with enhanced therapeutic index for fighting against immunosuppressive tumor microenvironment
R. Monjezi1, C. Miskey2, T. Stüber3, E. Grueso4, M. Schleef5, M. Schmeer5, H. Einsele1, Z. Ivics2, M. Hudecek1
1universitätsklinikum würzburg, Internal medizinische klinik und poliklinik ii, Würzburg, Germany
2Paul-Ehrlich-Institute, Division of Medical Biotechnology, Langen, Germany
3universitätsklinikum würzburg, Frauenklinik und Poliklinik, Würzburg, Germany
4Universidad Francisco de Vitoria, Department of Biotechnology, Pozuelo de Alarcón, Spain
5PlasmidFactory, PlasmidFactory, Bielefeld, Germany
_______________________________________________________

ICLE8-0024
Safety switches and controlled expression

Development of clinical-grade doxycycline-inducible CAR T cells
N. Maldonado1, M. Tristán-Manzano1, S. Sánchez-Hernández1, C. Marañón1, C. Herrera2, M.D. Carmona2, F. Martin1, K. Benabdellah1
1Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica GENYO, Genomic Medicine, Granada, Spain
2Unidad de Terapia Celular en Hospital Reina Sofía, Servicio Andaluz de Salud, Córdoba, Spain

_______________________________________________________

ICLE8-0025
Genome editing for allogeneic ACT

Generation of "off-the shelf" αCD19-CAR T cells for the treatment of B cell malignancies
M. Tristán-Manzano1, R. Martín-Guerra1, N. Maldonado1, S. Sánchez-Hernández1, M. Cortijo1, C. Marañon1, C. Herrera2, M.D. Carmona2, J.A. Marchal3, K. Benabdellah1, F. Martín1
1Centro Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica GENYO-, Genomic Medicine, Granada, Spain
2Unidad de Terapia Celular IMIBIC-HURS, Hospital Reina Sofía, Córdoba, Spain
3Centre for Biomedical Research CIBM-University of Granada, Human Anatomy and Embryology, Granada, Spain

_______________________________________________________

ICLE8-0028
Target and receptor discovery

A semi-automated method for the isolation and initial characterization of neoantigen-specific T cell receptors
A. Bracher1, D. Sommermeyer1
1Medigene Immunotherapies GmbH, T Cell Engineering, Planegg-Martinsried, Germany

_______________________________________________________

ICLE8-0030
Receptor and vector design

Overcoming fratricide to deliver a clinical grade CAR T cell product
S. Bornschein1, B. Demoulin1, E. Breman1, A. Michaux1, J. Houssa1, F. Huberty1, B. Violle1, C. Jacques-Hespel1, C. Marchand1, J. Marijsse1, T. Nguyen1, N. Ramelot1, D. Daro1, V. Steenwinckel2, S. Agaugue1, D. Gilham1
1Celyad, Research & Development, Mont-Saint-Guibert, Belgium
2Celyad, Industrialization, Mont-Saint-Guibert, Belgium

_______________________________________________________

ICLE8-0031
Other

EVALUATION OF A FULLY HUMAN CAR FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION IN AN IMMUNOCOMPETENT MOUSE MODEL
M. Festag1, K. Wisskirchen1,2, J. Hasreiter1, S. Schreiber1, H. Abken3, U. Protzer1,2
1Institute of Virology, Technische Universität München / Helmholtz Zentrum München, Munich, Germany
2German Centre for Infection Research DZIF, Munich partner site, Munich, Germany
3Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
_______________________________________________________

ICLE8-0038
Other

ARMING HUMAN REGULATORY T CELLS FROM HEALTHY DONORS OR MULTIPLE SCLEROSIS PATIENTS WITH SWITCHABLE CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
A. Kegler1, S. Koristka1, R. Bergmann1, C. Arndt1, A. Feldmann1, S. Albert2, G. Ehninger3,4,5, M. Bornhäuser3,4,5, M. Schmitz4,5,6, K. Akgün7, T. Ziemssen7, M. Bachmann1,2,4,5
1Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
2UniversityCancerCenter UCC 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany
3University Hospital 'Carl Gustav Carus' TU Dresden, Medical Clinic and Policlinic I, Dresden, Germany
4National Center for Tumor Diseases NCT, 'Carl Gustav Carus' TU Dresden, Dresden, Germany
5German Cancer Research Center DKFZ and German Cancer Consortium DKTK, partner site Dresden, Heidelberg, Germany
6Medical Faculty TU Dresden, Institute of Immunology, Dresden, Germany
7Center of Clinical Neuroscience University Hospital ´Carl Gustav Carus' TU Dresden, Department of Neurology, Dresden, Germany

_______________________________________________________

ICLE8-0039

Engineering HSC, NK, NKT and γδ T cells


NK CELLS FROM DIFFERENT SOURCES AS A PROMISING ALTERNATIVE FOR CAR-BASED IMMUNOTHERAPY AGAINST HEMATOLOGICAL CANCERS
L. Herrera1, A. Boronat2, P. Zuñiga1, I. Martin3, J. Anguita3, B. Marzal2, S. Santos1, M.A. Vesga1, F. Borrego4, M. Juan2, C. Eguizabal1
1Basque Center for Blood Transfusion and Human Tissues, Cell Therapy and Stem Cells Group, Galdakao- 48960- Spain, Spain
2Hospital Clínic - Sant Joan de Déu- UB- IDIBAPS, Immunotherapy Section. Servei d'Immunologia, 08036 Barcelona, Spain
3CIC bioGUNE, CIC bioGUNE, Derio- 48160- Spain, Spain
4Basque Center for Blood Transfusion and Human Tissues, Research Unit, Galdakao- 48960- Spain, Spain

_______________________________________________________

ICLE8-0040
Solid tumours

REDIRECTING SWITCHABLE UNICAR T CELLS FOR ELIMINATION OF RADIORESISTANT CANCER CELLS
A. Feldmann1, C. Arndt1, R. Bergmann1, N. Berndt2, J. Jureczek2, S. Albert3, D. Lindner3, S. Koristka1, J. Steinbach1,2, G. Ehninger2,4, M. Krause2,5,6, I. Kurth5, A. Dubrovska2,5,6, M. Bachmann1,2,3
1Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany
2German Cancer Research Center DKFZ and German Cancer Consortium DKTK, partner site Dresden, Heidelberg, Germany
3UniversityCancerCenter UCC 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany
4University Hospital 'Carl Gustav Carus' TU Dresden, Medical Clinic and Policlinic I, Dresden, Germany
5Medical Faculty TU Dresden, OncoRay - National Center for Radiation Research in Oncology, Dresden, Germany
6Helmholtz-Zentrum Dresden-Rossendorf HZDR, Institute of Radiooncology - OncoRay, Dresden, Germany

_______________________________________________________

ICLE8-0045
HIV

ANTIBODY-SECRETING T CELLS ENGINEERED FOR TRIPARTATE IMMUNE RESPONSE AGAINST THE HIV RESERVOIR
A. Powell1, Y. Ren2, M. Korom2, H. Goldstein3, D.F. Nixon2, C. Bollard4, R.M. Lynch2, R.B. Jones2, C.R. Cruz5
1George Washington University, Institute for Biomedical Sciences, Washington- DC, USA
2George Washington University, Institute for Microbiology- Immunology- and Tropical Medicine, Washington- DC, USA
3Albert Einstein College of Medicine, Department of Microbiology and Immunology, New York- New York, USA
4Children's National Medical Center, Center for Cancer & Immunology Research, Washington- DC, USA
5Children's National Medical Center, Department of Pediatrics, Washington- DC, USA

_______________________________________________________

ICLE8-0047
Genome editing for allogeneic ACT

GENOME EDITING USING ARCUS HOMING ENDONUCLEASES AND AN OPTIMIZED MANUFACTURING PROCESS FOR PRODUCTION OF OFF-THE-SHELF ALLOGENEIC CAR T THERAPIES
B. Mccreedy1, A. Martin1, D. MacLeod1, C. Pham1, A. Brown1, J.A. Hux1, J. Lape1, C. Beard1, J. Smith1, K. Nguyen1, V. Senyukov1, J. Anthony1, K. Sivarajan1, L. Som1, M. Triggiano1, D. Jantz1
1Precision BioSciences- Inc., Cell Therapy, Durham, USA